GLP Cagri + Sema Biostrategix Novo Nordisk's next generation weight loss drug CagriSema matches Lilly's Zepbound in major trial, but doesn't surpass it CNN PDF] Once weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double blind, placebo controlled and active controlled, dose finding phase 2 trial. Semantic Scholar Cagrilintide Combined with Semaglutide: A New Approach for Treatment of Obesity and Type 2 Diabetes ClinicSearch Another win for brain centric obesity treatment approaches. Adding cagrilintide (an amylin analog) to semaglutide (a GLP 1 analog) enhances weight loss. 17.1% weight loss over 20 wk at highest dose, with weight still